Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DEBIRITUX trial in refractory metastatic colorectal cancer with liver metastases
2009-014728-44Phase 2Suspended
- Sponsor
- Martin Luther University Halle-Wittenberg
- Start
- Nov 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in metastatic colorectal adenocarcinoma (mCRC) comparing DEBIRI chemoembolization plus cetuximab with Systemic irinotecan plus cetuximab (2 arms). Primary endpoint: Progression-free survival rate after 6 months. Started Nov 2009; status: suspended.
02
Drugs
irinotecancetuximab
03
Conditions
metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on 2009-014728-44.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-014728-44.